Retatrutide phase 3 results are among the most anticipated developments in obesity medicine, as this investigational triple receptor agonist from Eli Lilly moves through its TRIUMPH trial programme. Building on striking phase 2 data — which showed mean body weight reductions of approximately 24% at the highest dose over 48 weeks — retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, potentially offering a more powerful metabolic effect than existing treatments. This article explains how retatrutide works, summarises current clinical evidence, outlines its safety profile, and sets out the regulatory steps required before it could become available on the NHS.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, increase energy expenditure, and improve metabolic function. It has not yet received MHRA or EMA approval.

Retatrutide is an investigational injectable medication developed by Eli Lilly and Company, currently undergoing late-stage clinical evaluation for the treatment of obesity and related metabolic conditions. It belongs to a novel class of agents known as triple receptor agonists, distinguishing it from earlier-generation treatments such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist).

Specifically, retatrutide simultaneously activates three distinct hormone receptors:

• GLP-1 (glucagon-like peptide-1) receptors — promoting insulin secretion, reducing appetite, and slowing gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptors — enhancing insulin response and supporting fat metabolism

• Glucagon receptors — increasing energy expenditure and promoting hepatic fat breakdown

It is important to note that glucagon receptor activation can, in isolation, raise blood glucose levels; in retatrutide, this effect is thought to be offset by the concurrent GLP-1 and GIP receptor agonism, which promote insulin secretion. This balance is a key pharmacological consideration and is being evaluated further in ongoing trials.

The triple mechanism of action is hypothesised to produce a more pronounced and complementary effect on body weight and metabolic function than single or dual receptor approaches. Early-phase data have suggested potential benefits in conditions such as hepatic steatosis (fatty liver disease) and dyslipidaemia, which frequently accompany obesity; however, these remain investigational findings and have not yet been confirmed in large-scale trials.

In clinical trials, retatrutide has been administered as a once-weekly subcutaneous injection, consistent with other agents in its class (Jastreboff et al., NEJM, 2023). It is important to note that retatrutide has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains an investigational compound. All current data derive from clinical trial settings, and its use outside of approved trials is not sanctioned.

Key Findings from Phase 2 Trials and the Phase 3 Programme

Phase 2 data showed approximately 24% mean body weight reduction at the highest dose over 48 weeks; full Phase 3 TRIUMPH trial results are not yet available and are required before regulatory review.

The most closely watched data for retatrutide to date come from its Phase 2 clinical trial, published in The New England Journal of Medicine in 2023 (Jastreboff et al.), which demonstrated substantial weight reduction across dose groups. Participants receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks. These findings generated considerable scientific interest and supported progression into Phase 3 trials.

It should be noted that direct comparisons between retatrutide and other agents such as semaglutide or tirzepatide are not straightforward, as trials differ in design, population, duration, and endpoints. Cross-trial efficacy comparisons should therefore be interpreted with caution.

The Phase 3 programme, understood to be known as the TRIUMPH trials, is now underway and is evaluating retatrutide across broader and more diverse patient populations, including individuals with:

• Obesity without type 2 diabetes

• Obesity with type 2 diabetes

• Obesity-related cardiovascular disease

• Metabolic dysfunction-associated steatohepatitis (MASH)

Readers seeking the most current information on trial status, registered populations, and endpoints are encouraged to consult ClinicalTrials.gov directly, where Phase 3 trial registrations for retatrutide can be found. Full Phase 3 results are not yet available. The data anticipated from these trials will form the definitive evidence base required for regulatory review and clinical guideline development.

Beyond weight loss, Phase 2 data demonstrated improvements in HbA1c, fasting glucose, triglycerides, blood pressure, and waist circumference — all clinically relevant markers in the context of cardiovascular and metabolic risk. Whether these improvements are sustained and confirmed at Phase 3 scale remains to be established.

Clinicians and patients should interpret all preliminary findings with appropriate caution pending the full Phase 3 dataset.

Safety Profile and Reported Side Effects

The most common side effects in Phase 2 were dose-dependent gastrointestinal symptoms including nausea, vomiting, and diarrhoea; modest heart rate increases and gallbladder-related disorders were also observed at low frequency.

As with other incretin-based therapies, the most commonly reported adverse effects of retatrutide in Phase 2 trials were gastrointestinal in nature (Jastreboff et al., NEJM, 2023). These included:

• Nausea (most frequently reported)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally dose-dependent and transient, tending to occur during the dose escalation phase and resolving or diminishing over time. The trial protocol employed a gradual titration schedule specifically to mitigate gastrointestinal tolerability issues, a strategy consistent with approaches used for semaglutide and tirzepatide in clinical practice.

Severe or persistent gastrointestinal symptoms may, in some individuals, lead to reduced fluid intake and a risk of dehydration. Patients should be advised to maintain adequate hydration and to seek medical advice if symptoms are prolonged or severe.

More serious adverse events observed — though at low frequencies — included gallbladder-related disorders (such as cholelithiasis), which are a recognised class effect of GLP-1 receptor agonists. The addition of glucagon receptor agonism raises theoretical considerations around heart rate elevation, and Phase 2 data did show modest increases in resting heart rate in some participants — a finding that will require careful monitoring in Phase 3 cardiovascular outcome trials.

Injection-site reactions are a recognised consideration for subcutaneously administered agents of this class and will be further characterised in Phase 3 data.

Regarding thyroid safety: GLP-1 receptor agonists as a class have been associated with thyroid C-cell tumours in rodent studies, though the relevance of these findings to humans remains uncertain. The final regulatory wording for retatrutide — including any warnings or precautions relating to thyroid disease — has not yet been determined, as the medicine has not been approved. Patients with a personal or family history of thyroid conditions should discuss this with their clinical team. The UK Summary of Product Characteristics (SmPC) for approved GLP-1 receptor agonists such as semaglutide and tirzepatide provide relevant class-level context.

Patients participating in trials or considering future access should be advised to report any persistent or severe abdominal pain (which may indicate pancreatitis or gallbladder disease), unexplained changes in heart rate, or other concerning symptoms promptly to their clinical team.

Suspected adverse drug reactions to any medicine — including those encountered in clinical trials — can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. As Phase 3 safety data mature, a clearer long-term risk profile will emerge.

Regulatory Outlook and Potential NHS Availability

Retatrutide has not been submitted for regulatory approval in the UK; NHS availability depends on Phase 3 trial completion, MHRA marketing authorisation, and a positive NICE health technology appraisal, unlikely before the mid-to-late 2020s.

Retatrutide has not yet been submitted for regulatory approval in the United Kingdom or European Union. Its pathway to NHS availability will depend on the successful completion of Phase 3 TRIUMPH trials, followed by a marketing authorisation application to the MHRA (the UK's independent medicines regulator) and potentially the EMA for European markets. Based on the anticipated Phase 3 timelines, regulatory submissions are unlikely before the mid-to-late 2020s, though this is contingent on trial completion and data review processes; no confirmed submission date has been publicly announced by Eli Lilly at the time of writing.

Should retatrutide receive a positive regulatory decision, it would then be subject to a health technology appraisal (HTA) by NICE (National Institute for Health and Care Excellence) to determine its clinical and cost-effectiveness relative to existing treatments. NICE's published technology appraisals for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight management provide a framework illustrating the appraisal criteria against which retatrutide would be assessed. The bar for NHS commissioning is high, requiring demonstration of meaningful benefit over existing options at an acceptable cost per quality-adjusted life year (QALY).

It is also worth considering the NHS capacity context: the rollout of existing weight management medicines has been constrained by supply shortages and specialist service limitations. Any future introduction of retatrutide would need to be supported by adequate prescribing infrastructure, likely within Tier 3 or Tier 4 specialist weight management services, as outlined in NHS England's obesity care pathways.

For patients and clinicians following this area, the most reliable sources of updated information include the MHRA (gov.uk/mhra), NICE (nice.org.uk), NHS England, and peer-reviewed publications. Individuals interested in trial participation may wish to consult ClinicalTrials.gov or speak with their GP or specialist. No off-label or unregulated access to retatrutide is currently appropriate or sanctioned within the UK.

Frequently Asked Questions